HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Dec
20
ELECTIONS OF MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS
Dec
18
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF NEW DRUG APPLICATION FOR IRINOTECAN LIPOSOME INJECTION TO U.S. FDA
Dec
12
VOLUNTARY ANNOUNCEMENT - DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE ORALLY DISINTEGRATING TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Dec
01
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA
Nov
30
VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Nov
30
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Nov
29
POLL RESULTS OF THE FURTHER ADJOURNED EGM HELD ON 29 NOVEMBER 2023
Nov
27
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE SOS1 INHIBITOR (SYH2038) OBTAINS CLINICAL TRIAL APPROVAL
Nov
20
DATE OF BOARD MEETING
Nov
17
VOLUNTARY ANNOUNCEMENT - ALMB-0166 FOR TREATMENT OF ACUTE ISCHEMIC STROKE OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Nov
13
NOTICE OF FURTHER ADJOURNED EGM
Nov
10
FURTHER ADJOURNMENT OF EGM
Nov
06
VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Nov
03
ADJOURNMENT OF EXTRAORDINARY GENERAL MEETING NOTICE OF ADJOURNED EXTRAORDINARY GENERAL MEETING
Nov
03
VOLUNTARY ANNOUNCEMENT - MONOCLONAL ANTIBODY DRUG (SYS6011) OBTAINS CLINICAL TRIAL APPROVAL
Nov
01
VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Oct
30
VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL
Oct
25
VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Oct
24
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
Oct
09
NOTICE OF EXTRAORDINARY GENERAL MEETING
Oct
09
DESPATCH OF CIRCULAR IN RELATION TO (1) GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND (2) APPLICATION FOR WHITEWASH WAIVER
Sep
22
DELAY IN DESPATCH OF CIRCULAR
Sep
15
VOLUNTARY ANNOUNCEMENT - IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Sep
12
APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER
Sep
06
(REVISED) VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA
Sep
06
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR NARLUMOSBART FOR INJECTION (JMT103) APPROVED BY THE NMPA
Sep
04
GRANT OF SHARE OPTIONS UNDER THE SHARE OPTION SCHEME AND APPLICATION FOR WHITEWASH WAIVER
Aug
29
VOLUNTARY ANNOUNCEMENT - SEMAGLUTIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Aug
28
2023 INTERIM DIVIDEND
Aug
24
VOLUNTARY ANNOUNCEMENT - SACUBITRIL VALSARTAN SODIUM TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Aug
23
2023 INTERIM DIVIDEND
Aug
23
2023 INTERIM RESULTS
Aug
21
VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION AGREEMENTS IN THE FIELD OF ARTIFICIAL INTELLIGENCE (AI) IN INNOVATIVE DRUG RESEARCH AND DEVELOPMENT
Aug
17
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE HALF YEAR ENDED 30 JUNE 2023
Aug
17
VOLUNTARY ANNOUNCEMENT - NBL-028 FOR THE TREATMENT OF CLDN6 EXPRESSING ADVANCED TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Aug
11
DATE OF BOARD MEETING
Jul
04
VOLUNTARY ANNOUNCEMENT - DESVENLAFAXINE SUCCINATE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jul
03
VOLUNTARY ANNOUNCEMENT - RABEPRAZOLE SODIUM ENTERIC-COATED TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jun
29
VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION OF BATOCLIMAB (HBM9161) ACCEPTED BY THE NMPA
Jun
29
VOLUNTARY ANNOUNCEMENT - STRATEGIC PARTNERSHIP WITH PFIZER TO LAUNCH LOCAL BRAND OF ORAL ANTIVIRAL TREATMENT FOR COVID-19 IN CHINA
Jun
26
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF OMALIZUMAB FOR INJECTION
Jun
26
VOLUNTARY ANNOUNCEMENT - TEDIZOLID PHOSPHATE FOR INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Jun
26
VOLUNTARY ANNOUNCEMENT - CHINA'S FIRST ANTI-GFRAL MONOCLONAL ANTIBODY JMT203 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Jun
23
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
21
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
19
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME
Jun
14
VOLUNTARY ANNOUNCEMENT - PALIPERIDONE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jun
14
VOLUNTARY ANNOUNCEMENT - MIRABEGRON EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jun
12
VOLUNTARY ANNOUNCEMENT - SELECTIVE ATM INHIBITOR SYH2051 OBTAINS CLINICAL TRIAL APPROVAL
Jun
12
VOLUNTARY ANNOUNCEMENT - CPO301 WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
Jun
08
VOLUNTARY ANNOUNCEMENT - CPO301 OBTAINS CLINICAL TRIAL APPROVAL IN CANADA
May
31
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 31 MAY 2023
May
30
VOLUNTARY ANNOUNCEMENT - CLINICAL DATA OF ALMB-0168 FOR THE TREATMENT OF OSTEOSARCOMA TO BE PRESENTED AT THE 2023 ASCO ANNUAL MEETING
May
30
GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY
May
25
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2023
May
15
DATE OF BOARD MEETING
Apr
26
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF PRUSOGLIPTIN TABLETS
Apr
26
NOTICE OF ANNUAL GENERAL MEETING
Apr
25
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2023
Apr
20
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6010 OBTAINS CLINICAL TRIAL APPROVAL
Apr
02
VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE CPO301 OBTAINS CLINIAL TRIAL APPROVAL IN THE U.S.
Mar
27
VOLUNTARY ANNOUNCEMENT - "APREMILAST TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Mar
22
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
22
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022
Mar
22
VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
Mar
16
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2022
Mar
10
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF ENLONSTOBART FOR INJECTION
Mar
10
DATE OF BOARD MEETING
Mar
02
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE III CLINICAL TRIAL OF DUOENDA (MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION) FOR THE TREATMENT OF RECURRENT METASTATIC NASOPHARYNGEAL CARCINOMA
Feb
23
REMUNERATION COMMITTEE - TERMS OF REFERENCE
Feb
23
NOMINATION COMMITTEE - TERMS OF REFERENCE
Feb
16
VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA
Feb
13
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6002 WITH CORBUS PHARMACEUTICALS
Jan
19
VOLUNTARY ANNOUNCEMENT - OCTREOTIDE LONG-ACTING INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Jan
09
VOLUNTARY ANNOUNCEMENT - CLEVIDIPINE INJECTABLE EMULSION OBTAINS CLINICAL TRIAL APPROVAL
Jan
05
VOLUNTARY ANNOUNCEMENT - MELOXICAM NANOCRYSTAL INJECTION OBTAINS CLINICAL TRIAL APPROVAL
Jan
04
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PRMT5 INHIBITOR SYH2045 OBTAINS CLINICAL TRIAL APPROVAL

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer